Education & Research

Clinical Studies

You are here

Evidence for Benefits of CGM Use

Recognized as a standard of care in diabetes management by the American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE) and the Endocrine Society,1,2,3 continuous glucose monitoring (CGM) use has proven to both reduce A1C and time spent in hypoglycemia regardless of delivery method.4,5 Regular CGM use is also associated with an increase of time spent in range,4,6 a reduction of severe hypoglycemic incidents,7,8 and associated with many behavioral changes that promote significant positive change in diabetes self-management.9

HypoDE study shows that Dexcom CGM use significantly reduces hypoglycemia in MDI patients.1 Background

Continuous glucose monitoring (CGM) clinical trials to date have largely excluded individuals with severe hypoglycemia (SH) or...

In hypoglycemia unaware patients, CGM provides the required information needed for enhanced decision making support to improve glycemic control and help eliminate severe hypoglycemia. In this observational study, severe hypoglycemia incidents...

In this open-label, single-arm, multicenter clinical study, the Dexcom G4® PLATINUM Continuous Glucose Monitoring (CGM) System (which uses the same software 505 as the Dexcom G5 Mobile CGM System) was evaluated for accuracy in 51...

Persistent use of a continuous glucose monitoring (CGM) system is tied to the sensor accuracy, particularly in the pediatric population who experience greater glycemic variability and wider glycemic excursions than adults. Clinical peformance...

DIaMonD Study1 shows that Dexcom CGM use improves glucose control in adults with type 1 diabetes using insulin injections.

DIaMonD Type 1 Study Highlights (pdf)

Published in 2008, this landmark randomized, controlled trial conducted by JDRF was the first study to provide clear evidence of improved glycemic outcomes with the use of continuous glucose monitoring (CGM). The study showed that CGM use for at...

Pages

1

American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55-S64.

2

Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 Outpatient Glucose Monitoring
Consensus Statement. Endocr Pract. 2016;22(2):231-261.

3

Peters A, Ahmann A, Battelino T et al. Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016:jc.2016-2534.

4

Šoupal J, Petruželková L, Flekač M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538.

5

Battelino T PM, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes. Diabetes Care. 2011;34(4):795-800.

6

Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The diamond randomized clinical trial. JAMA. 2017;317(4):371-378. doi:10.1001/jama.2016.19975.

7

Choudhary P, Ramasamy S, Green L et al. Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care. 2013;36(12):4160-4162.

8

Lind M, Polonsky, W, Hirsch, I, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Injections – The GOLD Randomized Clinical Trial. [published January 2017]. JAMA.

9

Haas L, Maryniuk M, Beck J, et al. National Standards for Diabetes Self-Management Education and Support, Diabetes Care, Volume 35, November 2012